CN116711028A - Ac-225溶液的制造方法及使用了Ac-225溶液的医药的制造方法 - Google Patents

Ac-225溶液的制造方法及使用了Ac-225溶液的医药的制造方法 Download PDF

Info

Publication number
CN116711028A
CN116711028A CN202280008912.6A CN202280008912A CN116711028A CN 116711028 A CN116711028 A CN 116711028A CN 202280008912 A CN202280008912 A CN 202280008912A CN 116711028 A CN116711028 A CN 116711028A
Authority
CN
China
Prior art keywords
solution
solid
amount
complex
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280008912.6A
Other languages
English (en)
Chinese (zh)
Inventor
本田芳雄
伊藤拓
市濑润
市川浩章
今井智之
永津弘太郎
铃木寿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nihon Medi Physics Co Ltd
National Institutes For Quantum Science and Technology
Original Assignee
Nihon Medi Physics Co Ltd
National Institutes For Quantum Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Medi Physics Co Ltd, National Institutes For Quantum Science and Technology filed Critical Nihon Medi Physics Co Ltd
Publication of CN116711028A publication Critical patent/CN116711028A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G4/00—Radioactive sources
    • G21G4/04—Radioactive sources other than neutron sources
    • G21G4/06—Radioactive sources other than neutron sources characterised by constructional features
    • G21G4/08—Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical application

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • High Energy & Nuclear Physics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280008912.6A 2021-01-08 2022-01-05 Ac-225溶液的制造方法及使用了Ac-225溶液的医药的制造方法 Pending CN116711028A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021002437 2021-01-08
JP2021-002437 2021-01-08
PCT/JP2022/000116 WO2022149578A1 (ja) 2021-01-08 2022-01-05 Ａｃ－２２５溶液の製造方法およびＡｃ－２２５溶液を用いた医薬の製造方法

Publications (1)

Publication Number Publication Date
CN116711028A true CN116711028A (zh) 2023-09-05

Family

ID=82357768

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280008912.6A Pending CN116711028A (zh) 2021-01-08 2022-01-05 Ac-225溶液的制造方法及使用了Ac-225溶液的医药的制造方法

Country Status (10)

Country Link
US (2) US11752223B2 (https=)
EP (1) EP4276855A4 (https=)
JP (2) JP7154465B1 (https=)
KR (2) KR20230120627A (https=)
CN (1) CN116711028A (https=)
AU (1) AU2022206140A1 (https=)
CA (1) CA3207700A1 (https=)
TW (1) TW202235093A (https=)
WO (1) WO2022149578A1 (https=)
ZA (1) ZA202306906B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230390425A1 (en) * 2020-10-16 2023-12-07 Nihon Medi-Physics Co., Ltd. Radioactive complexes of anti-her2 antibody, and radiopharmaceutical
WO2026063503A1 (ja) * 2024-09-20 2026-03-26 日本メジフィジックス株式会社 Ａｃ－２２５溶液の製造方法および該溶液を用いたＡｃ－２２５標識錯体の製造方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194364A1 (en) * 2002-04-12 2003-10-16 Bond Andrew H. Multicolumn selectivity inversion generator for production of high purity actinium for use in therapeutic nuclear medicine
DE102006042191A1 (de) * 2005-09-09 2007-07-05 Actinium Pharmaceuticals, Inc. Verfahren zur Reinigung von Radium aus verschiedenen Quellen
CN101390171A (zh) * 2006-02-21 2009-03-18 艾科提医药公司 从辐照的226Ra-目标物中提纯225Ac的工艺
CN111052262A (zh) * 2017-06-29 2020-04-21 南非核能Soc有限公司 放射性同位素的制备

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07203974A (ja) 1994-01-13 1995-08-08 Tosoh Corp 癌特異的ムチンを認識する抗体の遺伝子断片等
JPH115749A (ja) 1997-06-13 1999-01-12 Tosoh Corp 癌治療医薬品組成物
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
ES2524767T3 (es) * 2002-06-14 2014-12-12 Immunomedics, Inc. Anticuerpo monoclonal humanizado HPAM4
DE10347459B3 (de) 2003-10-13 2005-05-25 Actinium Pharmaceuticals, Inc. Radium-Target sowie Verfahren zu seiner Herstellung
WO2005084179A2 (en) * 2003-12-01 2005-09-15 Immunomedics, Inc. Improved method for preparing conjugates of proteins and chelating agents
CA2950532C (en) 2006-09-08 2018-10-23 Actinium Pharmaceuticals, Inc. Method for the purification of radium from different sources
WO2013157102A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
WO2013157105A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
DE102014115154A1 (de) * 2014-10-17 2016-04-21 SCV-SpezialChemikalien-Vertrieb GmbH Konjugierte Bisphosphonate für die Diagnostik und Therapie von Knochenerkrankungen
ES3058443T3 (es) 2015-05-20 2026-03-10 Univ Kagoshima Modificación específica de anticuerpo con péptido de unión a IgG
DK3470418T3 (da) 2016-06-13 2024-09-30 Univ Kagoshima Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid
KR102924918B1 (ko) 2019-06-19 2026-02-10 니혼 메디피직스 가부시키가이샤 226Ra 타깃의 제조 방법, 225Ac의 제조 방법 및 226Ra 타깃 제조용 전착액
WO2021002275A1 (ja) * 2019-07-02 2021-01-07 日本メジフィジックス株式会社 ２２６Ｒａ含有溶液の精製方法、２２６Ｒａターゲットの製造方法および２２５Ａｃの製造方法
CA3148288A1 (en) 2019-08-21 2021-02-25 Nihon Medi-Physics Co., Ltd. Method for producing radioactive metal complex
JPWO2021075546A1 (https=) 2019-10-18 2021-04-22

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194364A1 (en) * 2002-04-12 2003-10-16 Bond Andrew H. Multicolumn selectivity inversion generator for production of high purity actinium for use in therapeutic nuclear medicine
DE102006042191A1 (de) * 2005-09-09 2007-07-05 Actinium Pharmaceuticals, Inc. Verfahren zur Reinigung von Radium aus verschiedenen Quellen
CN101390171A (zh) * 2006-02-21 2009-03-18 艾科提医药公司 从辐照的226Ra-目标物中提纯225Ac的工艺
CN111052262A (zh) * 2017-06-29 2020-04-21 南非核能Soc有限公司 放射性同位素的制备

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALFRED MORGENSTERN: "supply and clinical application of Actinium-225 and Bismuth-213", 《SEMINARS IN NUCLEAR MEDICINE》, vol. 50, no. 2, 21 February 2020 (2020-02-21), pages 1 - 5 *

Also Published As

Publication number Publication date
EP4276855A4 (en) 2025-08-06
JPWO2022149578A1 (https=) 2022-07-14
EP4276855A1 (en) 2023-11-15
US20230364275A1 (en) 2023-11-16
KR20230120627A (ko) 2023-08-17
AU2022206140A1 (en) 2023-07-27
CA3207700A1 (en) 2022-07-14
US11752223B2 (en) 2023-09-12
ZA202306906B (en) 2024-10-30
JP2022188190A (ja) 2022-12-20
WO2022149578A1 (ja) 2022-07-14
TW202235093A (zh) 2022-09-16
JP7846599B2 (ja) 2026-04-15
KR20220101191A (ko) 2022-07-19
US20220370651A1 (en) 2022-11-24
JP7154465B1 (ja) 2022-10-17
KR102500942B1 (ko) 2023-02-17

Similar Documents

Publication Publication Date Title
Ramogida et al. Evaluation of polydentate picolinic acid chelating ligands and an α-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced 225Ac
Loveless et al. Photonuclear production, chemistry, and in vitro evaluation of the theranostic radionuclide 47Sc
US20230364275A1 (en) METHOD FOR PRODUCING Ac-225 SOLUTION AND METHOD FOR PRODUCING MEDICINE USING Ac-225 SOLUTION
JP7402233B2 (ja) ガリウム６８を生成および／または精製するプロセスおよびシステム
Gott et al. A 224 Ra-labeled polyoxopalladate as a putative radiopharmaceutical
KR20220083768A (ko) 방사성 금속 표지 항체의 제조 방법
RU2768732C2 (ru) Способ получения изотопа
US20180158559A1 (en) Method and system for producing gallium-68 radioisotope by solid targeting in a cyclotron
Watanabe et al. Production of highly purified no-carrier-added 177Lu for radioimmunotherapy
Aliev et al. Separation of 167Tm, 165Er and 169Yb from erbium targets irradiated by 60 MeV alpha particles
RU2852721C1 (ru) СПОСОБ ПОЛУЧЕНИЯ РАСТВОРА Ac-225 и СПОСОБ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННОГО ПРЕПАРАТА С ИСПОЛЬЗОВАНИЕМ РАСТВОРА Ac-225
KR101451907B1 (ko) 역상 액체크로마토그래피를 이용한 루테튬-177의 분리방법
WO2018074918A1 (en) Isomeric transition radionuclide generator, such as a 177mlu/177lu generator
Montaña et al. Yttrium-90-current status, expected availability and applications of a high beta energy emitter
WO2022219431A2 (en) Process, apparatus and system for the production, separation and purification of radioisotopes
Bubenshchikov et al. The impact of zirconium‐89 solution formulation on the efficiency of [89Zr] Zr‐deferoxamine synthesis
Yang et al. Automated synthesis of [64Cu] Cu-NOTA-JR11 using a solid target medical cyclotron and its preclinical evaluation for SSTR imaging
KR100906781B1 (ko) Ｃｕ-64를 Ｇａ-67 생성물의 폐기물로부터 생산하는 방법
WO2026063503A1 (ja) Ａｃ－２２５溶液の製造方法および該溶液を用いたＡｃ－２２５標識錯体の製造方法
Laouameria Palladium-103 for Targeted Auger Electron Therapy: From Cyclotron Production and Innovative Separation to In Vivo Generator Evaluation and Preclinical Imaging
Ramos et al. Production of Mass-Separated
CN119095830A (zh) 放射性金属络合物的制造方法
Queern Radiolabeled Nanohydroxyapatite as a Platform for the Development of New PET Imaging Agents
HK40076208A (en) Method for producing radioactive metal-labeled antibody
HK1260173A1 (en) Isotope preparation method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination